The funding is available to institutions to support courses in genomic sciences and medicine, as well as the ethical, legal, and social implications of genomics.

An editorial at Scientific American calls for increased oversight of noninvasive prenatal genetic screens.

Get the latest news from PerkinElmer, Becton Dickinson, Premaitha Health, Sciex, Predictive Technology Group, Harvard Business School and Enzo Biochem for the week of 1/29/2016.

NantHealth is also planning to launch a 20,000-patient multi-arm, multi-drug trial based on profiling patients' tumors with its GPS Cancer test.

A type 2 diabetes genome-wide association meta-analysis involving tens of thousands of Japanese individuals uncovered risk loci relevant to other populations.

Combining PLA and mass cytometry, the method allows simultaneous measurement in the range of 40 to 50 RNAs and proteins in hundreds of thousands of cells.

The exchange warned the company that its stock could be delisted if it doesn't meet the $1.00 minimum required closing bid price.

Mass spectrometry has proven a worthy companion to methods like cryo-EM, but its true potential for structural analysis is only beginning to be realized.

Novogene will run the GenomeGuide RUO ancestry test on its Illumina HiSeq X Ten in Beijing. 

Researchers have found that normal tissue located near breast tumors exhibits epigenetic changes that may portend predisposition to disease.

In Science this week: zebrafish model of melanoma, and more.

The US District Court for the District of Arizona has granted Accelerate Dx's motion to dismiss a class-action lawsuit filed against it last year.

The pharmaceutical giant is aggressively incorporating the gene manipulating tech, especially in target validation and improving disease models.

Researchers from Brigham and Women's and Harvard surveyed more than 1,600 new customers of 23andMe or Pathway Genomics in the US, of whom 80 were adopted.

A scientist and former MP argues that Britain needs to stay in the European Union for science's sake.

President Obama has established the White House taskforce on cancer to be led by Vice President Biden.

The National Center for Biotechnology Information has released Sequence Viewer 3.11. This version of the tool includes bug fixes and new features such as the ability to overlay multiple graphs in one track, improved track descriptions, and updated SNP tracks. Additional details are provided in the release notes.

CentoGene has launched CentoBreast, its genetic testing panel that covers almost all hereditary forms of breast cancer, regardless of specific tumor syndrome. The panel includes genes frequently reported in association with familial form of breast cancer: BRCA1, BRCA2, TP53, PTEN, STK11, CDH1, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, and RAD51C. CentoBreast has a turnaround time of 10 working days and needs only 2μg DNA or 2 CentroCards, blood droplet sample collector.

Children's Hospital Los Angeles (CHLA) has appointed Jaclyn Biegel as the director of the Center for Personalized Medicine at CHLA. She is a professor of pathology at the Keck School of Medicine at the University of Southern California and also serves as chief of CHLA's new division of genomic medicine in the department of pathology and laboratory medicine. Previously, Biegel has served as director of the Cancer Cytogenetics Laboratory at Children's Hospital of Philadelphia and as a professor of pediatrics in the Perelman School of Medicine at the University of Pennsylvania.

Both studies found that about 40 percent of pediatric cancer patients have mutations with potential clinical significance, either for diagnosis or treatment.

The Centers for Medicare & Medicaid Services has sent a letter to Theranos that says some of its lab practices are deficient, and one poses "immediate jeopardy."

Fluidigm recently acknowledged that certain of its chips for the single-cell C1 system are capturing two cells, but is redesigning the chips to fix the problem. 

Roche's Diagnostics division had sales of CHF 10.81 billion ($10.67 billion) for the year  compared to CHF 10.77 billion in 2014.